Animal models of anorexia and cachexia

Expert Opinion on Drug Discovery

Volumn 4, Issue 11, 2009, Pages 1145-1155

  Deboer, Mark D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Animal models; Cachexia; Cancer; Chronic heart failure; Chronic kidney disease; Ghrelin; Melanocortin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GHRELIN; HORMONE RECEPTOR BLOCKING AGENT; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANOREXIA; CACHEXIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 72949102070     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903300842     Document Type: Review

References (85)

1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-1773
2. DeBoer MD, Marks DL. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2006;2:459-466
3. Laviano A, Meguid MM, Inui A, et al. Therapy insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol 2005;2:158-165
4. Huang QH, Hruby VJ, Tatro JB. Role of central melanocortins in endotoxin-induced anorexia. Am J Physiol 1999;276:R864-71
5. Marks DL, Butler AA, Turner R, et al. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 2003;144:1513-1523
6. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432-1438
7. O'Reilly B, Vander AJ, Kluger MJ. Effects of chronic infusion of lipopolysaccharide on food intake and body temperature of the rat. Physiol Behav 1988;42:287-291
8. Plata-Salaman CR, Oomura Y, Kai Y. Tumor necrosis factor and interleukin-1 beta: suppression of food intake by direct action in the central nervous system. Brain Res 1988;448:106-114
9. Kent S, Rodriguez F, Kelley KW, Dantzer R. Reduction in food and water intake induced by microinjection of interleukin-1 beta in the ventromedial hypothalamus of the rat. Physiol Behav 1994;56:1031-1036
10. Sonti G, Ilyin SE, Plata-Salaman CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996;270:R1394-402
11. Reyes TM, Sawchenko PE. Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. J Neurosci 2002;22:5091-5099
12. DeBoer MD, Scarlett JM, Levasseur PR, et al. Administration of IL-1beta to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides 2009;30:210-218
13. Otterness IG, Golden HW, Brissette WH, et al. Effects of continuously administered murine interleukin-1 alpha: tolerance development and granuloma formation. Infect Immun 1989;57:2742-2750
14. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11:400-407
15. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497
16. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005;8:265-269
17. DeBoer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab 2006;17:199-204
18. Fearon KCH, Moses AGW. Cancer Cachexia. Int J Cardiol 2002;85:73-81
19. Markison S, Foster AC, Chen C, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;146:2766-2773
20. Nicholson JR, Kohler G, Schaerer F, et al. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 2006;317:771-777
21. Jiang W, Tucci FC, Tran JA, et al. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2007;17:5610-5613 (Pubitemid 47391313)
22. Tran JA, Jiang W, Tucci FC, et al. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem 2007;50:6356-6366
23. Chen C, Tucci FC, Jiang W, et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem 2008;16:5606-5618
24. Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007;28:636-642
25. Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]- 4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004;47:1602-1604
26. Weyermann P, Dallmann R, Magyar J, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 2009;4:e4774
27. DeBoer MD, Zhu XX, Levasseur P, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007;148:3004-3012
28. Ramos EJ, Middleton FA, Laviano A, et al. Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg 2004;199:716-723
29. Wang Z, Wang W, Qiu W, et al. Involvement of ghrelin-growth hormone secretagogue receptor system in pathoclinical profiles of digestive system cancer. Acta Biochim Biophys Sin (Shanghai) 2007;39:992-998
30. Ramos EJ, Romanova IV, Suzuki S, et al. Effects of omega-3 fatty acids on orexigenic and anorexigenic modulators at the onset of anorexia. Brain Res 2005;1046:157-164
31. Goncalves CG, Ramos EJ, Romanova IV, et al. Omega-3 fatty acids improve appetite in cancer anorexia, but tumor resecting restores it. Surgery 2006;139:202-208
32. Rebeca R, Bracht L, Noleto GR, et al. Production of cachexia mediators by Walker 256 cells from ascitic tumors. Cell Biochem Funct 2008;26:731-738
33. Cahlin C, Korner A, Axelsson H, et al. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000;60:5488-5493
34. Argiles JM, Busquets S, Garcia-Martinez C, Lopez-Soriano FJ. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition 2005;21:977-985
35. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-106
36. Busquets S, Alvarez B, Van Royen M, et al. Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett 2000;157:99-103
37. Busquets S, Figueras MT, Fuster G, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004;64:6725-6731
38. Muscaritoli M, Costelli P, Bossola M, et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition 2003;19:936-939
39. Bibby MC, Double JA, Ali SA, et al. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 1987;78:539-546
40. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47:5919-5923
41. Wang W, Andersson M, Iresjo BM, et al. Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol 2006;28:1393-1400
42. Eden E, Lindmark L, Karlberg I, Lundholm K. Role of whole-body lipids and nitrogen as limiting factors for survival in tumor-bearing mice with anorexia and cachexia. Cancer Res 1983;43:3707-3711
43. Liang XM, Tang GY, Cheng YS, Zhou B. Evaluation of a rabbit rectal VX2 carcinoma model using computed tomography and magnetic resonance imaging. World J Gastroenterol 2009;15:2139-2144
44. DeBoer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008;149:827-835
45. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292-3301
46. Carbo N, Lopez-Soriano J, Tarrago T, et al. Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 1997;115:113-118
47. Piffar PM, Fernandez R, Tchaikovski O, et al. Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett 2003;201:139-148
48. Hanada T, Toshinai K, Date Y, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism 2004;53:84-88
49. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003;301:275-279
50. DeBoer M. Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition 2009. In press
51. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008;24:806-814
52. Van Norren K, Kegler D, Argiles JM, et al. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009;100:713-722
53. Von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-252
54. Anker S. Cachexia and cardiology. Circulation 2006;113:f53-4
55. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053
56. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-933
57. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51-66
58. Bowe DD, Scarlett JM, Basra AK, Steiner RA, Marks DL. Blockade of central melanocortin signaling promotes accumulation of lean body mass in rodent models of chronic heart failure. J Investig Med 2007;55:S77
59. Basra AK, Scarlett JM, Bowe DD, Steiner RA, Marks DL. Central melanocortin blockade attenuates cardiac cachexia in a rat model of chronic heart failure. J Investig Med 2008;56:229-230
60. Gould KE, Taffet GE, Michael LH, et al. Heart failure and greater infarct expansion in middle-aged mice: a relevant model for postinfarction failure. Am J Physiol Heart Circ Physiol 2002;282:H615-21
61. Akashi YJ, Palus S, Datta R, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol 2008 [E-pub ahead of print]
62. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001;104:1430-1435
63. Palus S, Akashi Y, Von Haehling S, et al. The influence of age and sex on disease development in a novel animal model of cardiac cachexia. Int J Cardiol 2009;133:388-393
64. Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 2003;9:464-468
65. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 2006;106:319-322
66. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 2006;21:229-233
67. Chertow GM, Johansen KL, Lew N, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000;57:1176-1181
68. Wang AY, Sea MM, Tang N, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004;15:3134-3143
69. Mak RH, Cheung W, Cone RD, Marks DL. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatr Nephrol 2005;20:427-431
70. Mak RH, Cheung W, Cone RD, Marks DL. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol 2006;2:527-534
71. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002;13(Suppl 1):S28-36
72. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002;110:437-439
73. Pickering WP, Price SR, Bircher G, et al. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 2002;61:1286-1292
74. Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005;115:1659-1665
75. Cheung WW, Kuo HJ, Markison S, et al. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol 2007;18:2517-2524
76. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008;74:180-186
77. Barazzoni R, Zhu XX, DeBoer MD, et al. Combined effects of ghrelin and attenuated anorexia enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int 2009. In press
78. Joppa MA, Gogas KR, Foster AC, Markison S. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 2007 [E-pub ahead of print]
79. Nelson K, Walsh D, Sheehan F. Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support Care Cancer 2002;10:455-461
80. Garcia JM, Cata JP, Dougherty PM, Smith RG. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008;149:455-460
81. Liu YL, Malik NM, Sanger GJ, Andrews PL. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 2006;58:326-333
82. DeBoer MD. Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 2007;10:457-462
83. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588
84. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009;360:44-52
85. Green EL, editor. Biology of the laboratory mouse. 2nd edition, Ben Harbor, Maine, The Jackson Laboratory; 1968